DENODO
23.6.2022 09:03:13 CEST | Business Wire | Press release
Denodo , the leader in data management, today announced that its customer LeasePlan, headquartered in the Netherlands and with business operations across the globe, has been chosen as the winner of the IDC’s 2022 European Data Strategy & Innovation Awards in the Data Management Excellence category. The winners were announced on June 9th, 2022 at the special awards ceremony as part of IDC’s 2022 European Data and Intelligence Summit in Sintra, Portugal.
IDC's European Data Strategy & Innovation Awards are focused on celebrating the European organizations that are blazing trails in this area and on improving awareness of "what works". According to Neil Ward-Dutton, VP AI, Automation and Analytics Europe, at IDC, "This is the third year of our European Data Strategy and Innovation Awards, and we were delighted to receive so many high-quality nominations from across the region."
IDC received 34 nominations for 3 award categories and LeasePlan edged past the other nominees in the Data Management excellence category to win the coveted title. According to IDC, "Nominations in this category were from enterprises that could demonstrate significant advances in their ability to manage data effectively and efficiently at scale. The overall winner was LeasePlan, for its creation of a logical data fabric across all its key data sources, which has helped the company in creating transformational new use cases in customer experience and convenience, such as predictive vehicle maintenance programs."
LeasePlan, one of the world’s leading Car-as-a-Service companies, has approximately 1.9 million vehicles under management in 29 countries. These vehicles generate a large amount of data that has to be integrated and contextualized to support the customer journey. What followed was LeasePlan’s next-gen data strategy, envisioned to encompass a logical data fabric across all its key data sources – modern, cloud-based and legacy – with a single point of access, to be supported by a Global Data Hub. According to Sumit Arya, the Head of Data and Solution Architecture at LeasePlan, “The Logical Data Fabric built on the Denodo Platform is a critical component of LeasePlan’s Global Data Hub to seamlessly build a foundation for data self-service and simplify transparent data migration. It has enabled us to create new business services and best support our drivers on every step of their journey.” Denodo Platform has also supported the data governance needs of the organization and facilitated its cloud modernization efforts with zero downtime for BI reporting while migrating legacy data marts to the Cloud in various business units across geographies.
“We want to congratulate our customer LeasePlan for its efforts and the innovative use of the Denodo Platform to support its data management needs and key business initiatives,” said Ravi Shankar, Senior Vice President and Chief Marketing Officer at Denodo. “The Denodo Platform provides an abstraction layer to create a single, secure point-of-entry to LeasePlan's entire data ecosystem. LeasePlan has also built a centralized framework for data governance by leveraging the metadata management and data catalog capabilities of the Denodo platform to ensure the highest level of self-service and data security. We are thrilled to see LeasePlan credited for the way they have applied our platform to make such an impact.”
Please Tweet : https://ctt.ac/hUnsp
About LeasePlan
LeasePlan, one of the world’s leading Car-as-a-Service companies, is transforming from an analogue to a fully digital business model. LeasePlan worked with Denodo and other technologies to create a logical data fabric across all its key data sources – modern, cloud-based and legacy – with a single point of access. This gives a foundation for data self-service and simplifies transparent data migration to the Cloud. Most notably, the data fabric approach has helped the company in creating transformational new use cases in customer experience and convenience, such as predictive vehicle maintenance programs.
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005168/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom